Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co)‎ obtained from treating coronavirus disease (COVID-19)‎ patients on the field

المؤلفون المشاركون

Fugazzola, Paola
Casadei, Chiara
Favi, Francesco
Tomasoni, Matteo
Zaghi, Claudia
Prosperi, Enrico
Sermonesi, Giacomo
Corbella, Davide
Pratico, Beniamino
Coccolini, Federico
Agnoletti, Vanni
Ansaloni, Luca

المصدر

Iranian Red Crescent Medical Journal

العدد

المجلد 22، العدد 7 (31 يوليو/تموز 2020)، ص ص. 1-12، 12ص.

الناشر

المستشفى الإيراني

تاريخ النشر

2020-07-31

دولة النشر

الإمارات العربية المتحدة

عدد الصفحات

12

التخصصات الرئيسية

الطب البشري

الملخص EN

Background: The Coronavirus Disease 2019 (COVID-19) pandemic has necessitated the alteration of the organization of entire hos- pitals to try to prevent them from becoming epidemiological clusters.

The adopted diagnostic tools lack sensitivity or specificity.

Objectives: The aim of the study was to create an easy-to-get risk score (Ri.S.I.Co., risk score for infection with the new coronavirus) developed on the field to stratify patients admitted to hospitals according to their risk of COVID-19 infection.

Methods: In this prospective study, we included all patients who were consecutively admitted to the suspected COVID-19 depart- ment of the Bufalini Hospital, Cesena (Italy).

All clinical, radiological, and laboratory predictors were included in the multivariate logistic regression model to create a risk model.

A simplified model was internally and externally validated, and two score thresh- olds for stratifying the probability of COVID-19 infection were introduced.

Results: From 11th March to 5th April 2020, 200 patients were consecutively admitted.

A Ri.S.I.Co lower than 2 showed a higher sensitivity than SARS-Cov-2 nucleic acid detection (96.2% vs.

65.4%; P < 0.001).

The presence of ground-glass pattern on the lung-CT scan had a lower sensitivity than a Ri.S.I.Co lower than 2 (88.5% vs.

96.2%; P < 0.001) and a lower specificity than a Ri.S.I.Co higher than 6 (75.0% vs.

96.9%; P < 0.001).

Conclusions: We believe that the Ri.S.I.Co could allow to stratify admitted patients according to their risk, preventing hospitals from becoming the main COVID-19 carriers themselves.

Furthermore, it could guide clinicians in starting therapies early in severe- onset cases with a high probability of COVID-19, before molecular SARS-CoV-2 infection is confirmed.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Fugazzola, Paola& Favi, Francesco& Tomasoni, Matteo& Zaghi, Claudia& Casadei, Chiara& Ansaloni, Luca…[et al.]. 2020. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal،Vol. 22, no. 7, pp.1-12.
https://search.emarefa.net/detail/BIM-1430509

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Ansaloni, Luca…[et al.]. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal Vol. 22, no. 7 (Jul. 2020), pp.1-12.
https://search.emarefa.net/detail/BIM-1430509

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Fugazzola, Paola& Favi, Francesco& Tomasoni, Matteo& Zaghi, Claudia& Casadei, Chiara& Ansaloni, Luca…[et al.]. Development and validation of a new risk score for infection with coronavirus (Ri.S.I.Co) obtained from treating coronavirus disease (COVID-19) patients on the field. Iranian Red Crescent Medical Journal. 2020. Vol. 22, no. 7, pp.1-12.
https://search.emarefa.net/detail/BIM-1430509

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references : p. 11-12

رقم السجل

BIM-1430509